Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis

Abstract

Although several studies have suggested that anti-inflammatory strategies reduce secondary infarct growth in animal stroke models, clinical studies have not yet demonstrated a clear benefit of immune modulation in patients. Potential reasons include systematic differences of post-ischemic neuroinflammation between humans and rodents. We here performed a systematic review and meta-analysis to summarize and compare the spatial and temporal distribution of immune cell infiltration in human and rodent stroke. Data on spatiotemporal distribution of immune cells (T cells, macrophages, and neutrophils) and infarct volume were extracted. Data from all rodent studies were pooled by means of a random-effect meta-analysis. Overall, 20 human and 188 rodent stroke studies were included in our analyses. In both patients and rodents, the infiltration of macrophages and neutrophils preceded the lymphocytic influx. Macrophages and neutrophils were the predominant immune cells within 72 h after infarction. Although highly heterogeneously across studies, the temporal profile of the poststroke immune response was comparable between patients and rodents. In rodent stroke, the extent of the immune cell infiltration depended on the duration and location of vessel occlusion and on the species. The density of infiltrating immune cells correlated with the infarct volume. In summary, we provide the first systematic analysis and comparison of human and rodent post-ischemic neuroinflammation. Our data suggest that the inflammatory response in rodent stroke models is comparable to that in patients with stroke. However, the overall heterogeneity of the post-ischemic immune response might contribute to the translational failure in stroke research.

Introduction

Stroke is a leading cause of death, long-term disability, and cognitive impairment worldwide [1, 2]. Recanalization of the occluded vessel either by pharmacological treatment with tissue plasminogen activator or by thrombectomy is the only therapeutic option to reduce poststroke brain tissue damage and to improve the clinical outcome [3]. Within the past years, the local post-ischemic inflammatory response, i.e., neuroinflammation, was identified as a key pathophysiological element that contributes to secondary brain damage after stroke [4, 5]. This immune response includes the infiltration of circulating leukocytes as well as the activation of local microglia [4,5,6]. Extensive experimental evidence in animal models demonstrates that different anti-inflammatory strategies reduce secondary infarct growth and therefore represent a promising therapeutic target [7,8,9]. Recently, clinical trials have been initiated to test immunomodulatory treatments in patients with stroke [10,11,12,13]. Results were, however, controversial: while two small trials testing fingolimod have been promising, larger studies testing natalizumab (Anti-VLA4) and enlimomab (Anti-ICAM-1) did not demonstrate a benefit [14]. Recently, pivotal study design differences between experimental studies and clinical trials were shown to contribute to the stepwise efficacy decline of stroke treatments from experimental studies to phase 3 clinical trials [15]. In addition, the question arises whether systematic differences in the poststroke immune response between humans and rodents might contribute to the translational failure. However, systematic comparisons of post-ischemic neuroinflammation between patients and animal models are lacking. In contrast to the local immune response, differences in blood leukocyte composition between humans and rodents are well established. Circulating neutrophils predominate in humans (50–70%), while in rodents, circulating leukocytes mainly consist of lymphocytes (75–90%) [16]. Besides potential differences between humans and animals, poststroke neuroinflammation and the efficacy of anti-inflammatory treatments differ substantially among commonly used animal stroke models suggesting that this heterogeneity contributes to the translational failure [17, 18]. Altogether, single studies analyzing the post-ischemic immune cell infiltration revealed inconclusive results. Hence, we performed a systematic review and meta-analysis to summarize and compare all available published studies on the spatial and temporal distribution of immune cell infiltration in human and rodent stroke.

Materials and Methods

Search Strategy

In accordance with PRISMA guidelines, we searched the database PUBMED from its inception date to February 2019. This strategy included the keywords “cerebral ischemia” OR “stroke” OR “cerebral infarct” AND “leukocytes” OR “lymphocytes” OR “granulocytes” OR “neutrophils” OR “monocytes” OR “macrophages.” We included only articles in English and German. The bibliographies of relevant articles were cross-checked for further articles not referenced in the aforementioned database. We excluded editorials, conference abstracts, and review papers. This study is registered with *PROSPERO, number CRD42019142603.

Inclusion/Exclusion Criteria

We included all studies, in which immune cell infiltration (lymphocytes and/or macrophages and/or neutrophils) after human or rodent stroke was quantified by either immunohistochemistry or flow cytometry. We focused on lymphocytes, macrophages, and neutrophils, which are regarded as the main players in the post-ischemic inflammatory response. Included studies in this meta-analysis and review were based on the following criteria: (1) measurement of the amount of cells per given unit; (2) quantification was performed at a certain time point; and (3) permanent or transient middle cerebral artery occlusion (pMCAO or tMCAO), photothrombotic stroke, or other focal stroke models were performed on rodents. The exclusion criteria were the following: (1) the study was based on experiments with neonatal rodents; (2) hemorrhagic stroke models, models with global cerebral ischemia or hypoxic ischemia; and (3) the study was based on experiments with animals other than rodents. To diminish systematical bias, human stroke studies with less than 3 patients were excluded.

Data Extraction

Two reviewers (CB and ASP) independently screened titles/abstracts of studies retrieved using the search strategy and extracted data from eligible studies into a standardized form. Any discrepancies were resolved by consensus or by consultation with a third reviewer (JM). Extracted data included animal stroke model, assessed region, time of cell count, analyzed cell type (lymphocytes, macrophages, or neutrophils), assessment method, immunostaining, cell quantification, infarct size, and the number of animals in the trial. When treatment was compared to control groups, only data of control groups were used. In histological analysis in rodent stroke models, the cell numbers were calculated as cells per mm3 and differences in the coronal section thickness were considered. Macrophages were identified by description of cell type within the different studies and cell staining. Studies using typical microglial marker, e.g., Iba1, were excluded. However, macrophages share several antigens with microglia cells, and thus, a reliable distinction between the different cell types is not always possible. Regarding fluorescence-activated cell sorting (FACS), only analyses of the ipsilateral brain hemisphere providing cell counts in cells per hemisphere were included. If CD4+ and CD8+ lymphocytes were mentioned separately, cell counts were added up to the total count of lymphocytes. The same applies for addition of M1 and M2 macrophages. For purpose of comparison, infarct volumes were only extracted in histological studies. If infarct volumes were reported as percentage of contralateral hemisphere, data were calculated in mm3 considering standard brain volume of mice [19,20,21,22] and rats [23,24,25]. Standard brain volumes were calculated from different mice and rat strains. When data were presented only graphically, values were read off the graphics using Adobe Acrobat X Pro (Adobe Systems; San Jose, CA).

In human stroke studies, obtained data included the number of patients in the trial, brain tissue source, days after stroke onset, analyzed cell type, analyzed region (e.g., ischemic core or penumbra), quantification/description of immune cell infiltration, and clinical information.

Statistical Methods

We performed meta-analyses to illustrate the spatiotemporal distribution of immune cell infiltration in experimental stroke. We extracted mean values and their standard errors (SEs) for immune cell infiltration at a certain point of time after stroke induction. If not provided directly, the SE was computed by dividing the standard deviation by the square root of the number of animals per group. A meta-analysis could only be performed for rodent studies. Human studies often provided semiquantitative values for cell counts and therefore did not allow calculations with means of meta-analysis. Random-effects meta-analysis (DerSimonian-Laird method) was conducted using the metafor package in R (version 3.5.0). In order to quantify the heterogeneity of the collected data, I2 has been calculated for each item under investigation. Meta-regression analysis was performed after logarithmic transformation of the mean number of immune cell population and mean infarct volume values in mice and rats using “metareg” function in the “meta” package in R. In all analyses, a value of p < 0.05 was considered to represent a significant difference.

Results

Included Studies and General Study Characteristics

Our initial search of the literature and reference lists of included studies yielded a total of 17,463 studies (Fig. S1). Of these, 10,387 duplicates were removed, and 7076 records were screened for eligibility through title and abstract review. We excluded 6851 records that were not relevant to the research objectives; these articles, for example, reported on heat stroke or global/hypoxic cerebral ischemia. Following a thorough review of the full-text articles and after quality assessment, our search yielded 225 studies, of which 205 were eligible for inclusion: 188 studies in mice and rats and 20 human studies (with an overlap of 3 studies that reported outcomes for both animals and humans).

Outcomes in experimental studies were assessed in 120 studies for infiltration of neutrophils, 92 studies for infiltration of macrophages, 49 studies for infiltration of lymphocytes, and 126 studies for infarct size (Table S1). In human studies, outcome was assessed in 11 studies for infiltration of neutrophils, 13 studies for infiltration of macrophages (in 2 studies microglia/macrophages), and 7 studies for infiltration of lymphocytes.

Immune Cell Infiltration in Human Stroke

Baseline characteristics of included human stroke studies are shown in Table 1. Some of the human studies provided clinical data on age (17 studies), sex (15 studies), vascular territory (11 studies), stroke etiology (4 studies), and cause of death (4 studies). The mean age of patients with stroke was 73.5 years (standard deviation, SD 7.8). The proportion of women was 55%. The middle cerebral artery territory was the most commonly affected vascular territory. The data of immune cell infiltration in human stroke were heterogeneous (Table 2). Three studies provided a mere descriptive analysis of immune cell infiltration. In eight studies, a semiquantitative scoring system was applied to describe the histological findings and to evaluate the intensity or extent of the inflammatory response. Nine studies reported numerical data of immune cells within the infarcted tissue. Time period from onset of stroke to death varied between a few hours and several months. However, most studies did not report the explicit interval between stroke and death.

Table 1 Baseline characteristics of included human stroke studies
Table 2 Spatiotemporal distribution of immune cells in human stroke studies

Among the human studies reporting histological data, different monoclonal antibodies for immunohistochemical staining were used. The most common antibody for macrophages was anti-CD68. Lymphocytes and their subsets were determined with anti-CD3, anti-CD4, and anti-CD8 antibodies. The immunostaining of neutrophils varied widely (e.g., hematoxylin-eosin, CD15, or neutrophil elastase). Four studies did not report the type of staining. Descriptions and terminology of the analyzed region varied widely. The assessed region was defined as infarcted area, peri-infarct region, ischemic core, or brain parenchyma.

Overall, the number of lymphocytes, macrophages, and neutrophils was higher in the infarcted area compared to the peri-infarct region (Table 2). Macrophages accumulated in the early phase (day 1) after stroke onset within both the ischemic core and in smaller numbers within the peri-infarct region. Some studies report macrophage infiltration not until 3 days after cerebral ischemia with a peak 7 days after stroke onset. Microscopically, accumulation of macrophages was observed around blood vessels as well as in the perivascular space. In most studies, neutrophil infiltration peaked at days 2 and 3 after stroke onset. In contrast, Sörnäs et al. found a strong neutrophil infiltration 5–6 days after stroke and only a mild earlier infiltration [26]. Additionally, in 4 out of 11 studies analyzing the neutrophil infiltration, the vast majority of neutrophils were detected within the lumen of blood vessels and the perivascular or leptomeningeal space of the infarcted area [30, 40, 41, 45]. Enzmann and colleagues found neutrophils in rather low counts or even completely absent within the infarcted brain parenchyma in very acute lesions (< 48 h) [40]. Overall, the number of infiltrating lymphocytes was lower compared to macrophages and neutrophils (Table 2). However, due to the few and heterogenous data on lymphocytes, conclusions on their spatiotemporal distribution are limited.

Immune Cell Infiltration in Rodent Stroke

Neutrophils started to appear within 24 h after ischemia and peaked at day 2 in FACS and at day 3 in histological analyses (Fig. 1a). A noticeable decline of immigrated neutrophils occurred from days 4 to 7 (Fig. 1a). Neutrophil counts within the infarct core seem to be higher in rats compared to mice, whereas there are slightly higher cell counts in mice within the penumbra (Fig. 1b, c). The temporal profile of macrophage infiltration revealed an early influx with a peak at day 2 and a second peak at day 4/5(Fig. 1). Cell counts did not decrease until day 7 after stroke induction. In the penumbra, macrophage cell counts seem to be slightly elevated in rats in relation to mice (Fig. 1c). Comparing different experimental stroke models showed that on days 1 and 7 poststroke, the cell count of infiltrated macrophages was lower in proximal permanent in contrast to proximal transient stroke models (Fig. 2a–c). The same applies for the number of neutrophils within the penumbra on days 1 and 2 poststroke (Fig. 2c). Interestingly, on days 2 and 3, this difference disappears, and cell counts are nearly identical with a slight tendency towards higher cell counts in proximal permanent stroke models (Fig. 2c). In distal permanent stroke models, cell counts of macrophages and neutrophils seem to reach the highest peak numbers in the peri-infarct region compared to other stroke models (Fig. 2c). This finding holds not true for cell counts in FACS analysis and infarct core (Fig. 2a, b). However, comparison of different stroke models and the comparison of animals and patients may be limited by the preponderance of data from proximal transient stroke models.

Fig. 1
figure1

Temporal and quantitative characterization of immune cell infiltration in rodent stroke at days 1–7 after induction of ischemia. Flow cytometric analysis of the ipsilateral brain hemisphere (a) and histological analysis (b infarct core, c penumbra) showing the absolute numbers (bare circles) of infiltrating immune cells (macrophages, neutrophils, and T cells) in the ischemic hemisphere in rats (blue) and mice (green). Meta-analyzed data are shown as mean with higher and lower 95% confidence interval. In case of negative confidence intervals, lower confidence limits are not shown. For clarity, data are shown as data of 10 (logarithmic scale)

Fig. 2
figure2

Immune cell infiltration in relation to animal stroke model at days 1–7 after induction of ischemia. Flow cytometric analysis of the ipsilateral brain hemisphere (a) and histological analysis (b infarct core, c penumbra) showing the absolute numbers of infiltrating immune cells (macrophages, neutrophils, and T cells) in the ischemic hemisphere for each type of ischemia: distal permanent (bare triangle), proximal transient (bare circle), distal transient (bare square), and proximal permanent (bare rhombus). Meta-analyzed data are shown as mean with higher and lower 95% confidence interval (red). In case of negative confidence intervals, lower confidence limits are not shown

T cells appeared in small amounts within 24 h and slightly increased until day 4 (Fig. 1a–c). The peak number of T cells on the first 2–4 days poststroke was nearly identical to the amount at day 7, indicating that T cells reach a plateau in ischemic tissue (Fig. 1a, c). In contrast, histological analysis of the infarct core showed a peak of infiltration on day 4 (Fig. 1b). Analyses of distinct experimental stroke models did not show any significant differences regarding the amount and distribution of infiltrating T cells (Fig. 2).

We found that macrophages were the most numerous cell type infiltrating the brain throughout the first 72 h and particularly at day 7 after induction of cerebral ischemia (Fig. 1). However, there were higher numbers of neutrophils on day 2 detected by FACS analysis (Fig. 1a). Our results indicate that the infiltration of the ischemic hemisphere by macrophages and neutrophils precedes the lymphocytic influx. Interestingly, immunohistochemical analysis revealed comparable peak cell counts of macrophages and T cells within the infarct core compared to the peri-infarct region (Fig. 1b, c).

We next performed a correlation analysis of the density (cells/mm3) of infiltrated immune cells with the infarct volume (Fig. 3). Meta-regression analysis did not indicate any significant association between immune cell density and infarct volume.

Fig. 3
figure3

Meta-regression analysis of the association between immune cell density of macrophages/microglia, neutrophils, or T cells and infarct volume 1–42 days after induction of ischemia. Due to the significant difference in infarct size, values for mice (a) and rats (b) are calculated separately. Values represent numbers of immune cells/mm3 in the infarct core and infarct volume in mm3

Summary and Comparison of Immune Cell Infiltration in Human and Rodent Stroke

Based on the analyses of this study, we summarized our findings on the temporal infiltration of immune cells in humans and rodents as shown in Fig. 4. Overall, the temporal dynamics of post-ischemic neuroinflammation is comparable in humans and rodents. However, there are certain findings that need to be elucidated. First, in experimental stroke, both cell count and relative distribution of immune cells are determined by the modality of analysis (histology vs. FACS) used. In FACS analysis, neutrophils were the most abundant immune cells within the first days after stroke induction (Fig. 4c). Furthermore, FACS analysis revealed a dual-wave-like infiltration of macrophages different to the slight increase and rather late peak in histological analysis. Second, comparison of infarct core and penumbra in histological animal studies demonstrates significant differences regarding the proportion of immune cell subsets after cerebral ischemia (Fig. 4a, b). For instance, the increase of T cells is more pronounced in the infarct core than in the penumbra. Besides differences within experimental stroke studies, our study identifies a temporal distribution pattern in human stroke slightly distinct from the immune cell response in rodent stroke studies (Fig. 4d). Of note, macrophages are rather slightly increasing in human stroke lesions suggesting a less pronounced role in the early phase poststroke. Nevertheless, it must be taken into account that the early and high peak of macrophage infiltration in human stroke might be explained by histological staining that potentially includes microglia.

Fig. 4
figure4

Schematics of temporal profile of immune cell infiltration in rodent (a, b, c) and human (b) stroke. Curves are created from data obtained from this study. In rodent stroke, numbers of immune cells are graphically calculated from the original data of histological (cells/mm3; a, b) and of FACS analysis (cells per ischemic hemisphere; c)

Discussion

In this systematic review and meta-analysis, we summarize data on post-ischemic neuroinflammation from 188 rodent and 20 human studies. Our analyses yield the following main findings: (1) temporal dynamics of immune cell infiltration is comparable after human and rodent stroke; (2) in rodent stroke, post-ischemic immune cell infiltration by macrophages and neutrophils preceded the lymphocytic influx and macrophages and neutrophils were the most numerous immune cell subtypes within 72 h after the onset of ischemia; (3) immune cell infiltration was highly heterogenous across human as well as rodent studies; and (4) counts of macrophages and in part of neutrophils are higher in proximal transient compared to proximal permanent stroke models on days 1 and 7 after ischemia.

Although the post-ischemic neuroinflammation of major immune cell subsets is comparable between rodents and humans, the translation of experimental anti-inflammatory stroke therapies into an effective treatment for patients has so far not been successful. Our study provides possible explanations for this translational failure. We identified heterogenous findings among the immune cell infiltration across rodent stroke studies. For instance, after proximal transient (60 min) ischemia in mice macrophage counts in FACS, analyses were threefold higher at 24 h in some studies compared to others. Counts of neutrophils were 2.5 times higher in proximal permanent compared to proximal transient stroke models in mice 24 h after stroke induction. Besides discrepancies regarding the absolute cell counts at certain time points after stroke induction, we also identified differences in the peak of immune cell infiltration. For instance, in some studies, neutrophils already peak 48 h after stroke induction, whereas others describe the peak of neutrophilic influx at 72 h after infarction. In addition, the role and significance of certain types of immune cells in ischemic stroke is controversial. For example, while B cells were recently reported to have a potential neuroprotective function in murine experimental stroke [46], separate studies could not confirm this observation suggesting that B cells play a lesser role in ischemic stroke [47, 48]. The same applies for studies on the effects of unselective macrophage depletion after stroke. A recent study showed that both selective and unselective monocyte/macrophage depletion and macrophage transfer did not influence tissue damage in the acute phase after experimental stroke, whereas different studies revealed beneficial as well as detrimental effects [49,50,51]. The discrepancies in experimental poststroke immune response could be a potential reason why in certain animal models immunomodulatory agents are beneficial and in others not. Apart from the differences in experimental setup and post-ischemic neuroinflammation in murine stroke models, heterogenous results due to different types of stroke, i.e., with or without recanalization, proximal or distal vessel occlusion, gray and/or white matter affected, can also be found in human stroke. Hence, these different conditions in human stroke, which cannot be validly represented by a certain experimental stroke model, lead to distinct results in poststroke immune cell response. Considering heterogeneity across human studies, detailed stroke characteristics are either missing or highly variable. For instance, the localization of the ischemic lesion (white vs. gray matter; forebrain vs. cerebellar vs. brain stem infarction), that is highly relevant for the clinical syndrome and functional outcome, is either not considered in the analysis of neuroinflammatory response or even merely reported. Another aspect is that occlusion pattern differs between animal models and patients with stroke. In particular, transient proximal occlusions are mainly performed in animal models, whereas patients more often have permanent proximal but also permanent distal occlusions. Furthermore, it is worth noting that in experimental stroke studies, the main focus is frequently on infarct size, although this reflects reality in human conditions only to a limited extent. In human stroke, the localization of the ischemic lesion within particular connections may be more relevant for the clinical symptoms and functional outcome. Furthermore, animals predominantly used in experimental stroke studies are young and healthy, whereas the typical stroke patient is aged and comorbid. Modeling stroke-associated risk factors, such as hypertension, diabetes, and hyperlipidemia, is important to model the immune system in human stroke given they profoundly affect the immune system and functional recovery. Experimental studies with aged animals demonstrated that neurological impairment increases, whereas the regenerative capacity is lowered compared to younger animals [52]. Moreover, preclinical studies on animals of both sexes in order to identify sex-based differences are lacking. Sex is known to display an important factor significantly affecting stroke incidence and outcome [53]. A potential solution to this dilemma could be the inclusion of selected, homogenous stroke patients with similarities to animal stroke studies and vice versa. In this context, noninvasive inflammation imaging in order to identify homogenous stroke patients with a proven local inflammatory response might support patient selection for clinical studies [54].

Our study has strengths and limitations. First, data on poststroke neuroinflammation in patients are mainly derived from small studies in which only a few time points after stroke were evaluated. In addition, some human studies provided only semiquantitative analyses of immune cells. Therefore, human studies could not be summarized by means of meta-analysis. A further limitation of our study is the focus on the acute phase after stroke, while it was demonstrated that the inflammatory response also affects long-term recovery. However, only a few studies on inflammatory changes later than 7 days after stroke were published which do not allow using meta-analysis techniques. Moreover, due to the small sample size and heterogeneity, statistical significance could not be determined for comparison between groups and hence analysis was based on visual interpretation of the graph. Nevertheless, a strength of our study is the large number of included animal studies allowing a more comprehensive analysis of temporal and spatial dynamics of poststroke neuroinflammation compared single studies.

Conclusion

In summary, this systematic review and meta-analysis represents the first systematic analysis and comparison of human and rodent studies on post-ischemic neuroinflammation. Basically, the inflammatory response in rodent stroke models is comparable to that in patients with stroke. However, the heterogeneity of the post-ischemic immune response depending on the duration and location of the vessel occlusion and the mode of ischemia induction might contribute to the translational failure in stroke research. Therefore, stroke patients selected for future studies should be more homogenous and better comparable to animal models in corresponding experimental studies.

References

  1. 1.

    Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371:1612–23.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009;8:1006–18.

    PubMed  Article  Google Scholar 

  3. 3.

    Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–99.

  4. 4.

    Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med. 2011;17:796–808.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67:181–98.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe C-U, Siler DA, et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40:1849–57.

    PubMed  Article  Google Scholar 

  7. 7.

    Strecker J-K, Minnerup J, Gess B, Ringelstein EB, Schäbitz W-R, Schilling M. Monocyte Chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1β and G-CSF after transient focal ischemia in mice. PLoS One. 2011;6:e25863.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Schilling M, Strecker J-K, Schäbitz W-R, Ringelstein EB, Kiefer R. Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice. Neuroscience. 2009;161:806–12.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Mizuma A, Yenari MA. Anti-inflammatory targets for the treatment of reperfusion injury in stroke. Front Neurol. 2017;8:467.

    PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Zhu Z, Fu Y, Tian D, Sun N, Han W, Chang G, et al. Combination of the immune modulator fingolimod with alteplase in acute ischemic stroke: a pilot trial. Circulation. 2015;132:1104–12.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Fu Y, Zhang N, Ren L, Yan Y, Sun N, Li Y-J, et al. Impact of an immune modulator fingolimod on acute ischemic stroke. Proc Natl Acad Sci U S A. 2014;111:18315–20.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2017;16:217–26.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Enlimomab Acute Stroke Trial Investigators. Use of anti-ICAM-1 therapy in ischemic stroke: results of the enlimomab acute stroke trial. Neurology. 2001;57:1428–34.

    Article  Google Scholar 

  14. 14.

    Veltkamp R, Gill D. Clinical trials of immunomodulation in ischemic stroke. Neurother J Am Soc Exp Neurother. 2016;13:791–800.

    CAS  Google Scholar 

  15. 15.

    Schmidt-Pogoda A, Bonberg N, Koecke MHM, Strecker J-K, Wellmann J, Bruckmann N-M, et al. Why Most acute stroke studies are positive in animals but not in patients: a systematic comparison of preclinical, early phase, and phase 3 clinical trials of neuroprotective agents. Ann Neurol. 2020;87:40–51.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  16. 16.

    Mestas J, Hughes CCW. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–8.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Zhou W, Liesz A, Bauer H, Sommer C, Lahrmann B, Valous N, et al. Postischemic brain infiltration of leukocyte subpopulations differs among murine permanent and transient focal cerebral ischemia models. Brain Pathol. 2013;23:34–44.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Llovera G, Hofmann K, Roth S, Salas-Pérdomo A, Ferrer-Ferrer M, Perego C, et al. Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia. Sci Transl Med. 2015;7:299ra121.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  19. 19.

    Roderick TH, Wimer RE, Wimer CC, Schwartzkroin PA. Genetic and phenotypic variation in weight of brain and spinal cord between inbred strains of mice. Brain Res. 1973;64:345–53.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Hammelrath L, Škokić S, Khmelinskii A, Hess A, van der Knaap N, Staring M, et al. Morphological maturation of the mouse brain: an in vivo MRI and histology investigation. NeuroImage. 2016;125:144–52.

    PubMed  Article  Google Scholar 

  21. 21.

    Badea A, Ali-Sharief AA, Johnson GA. Morphometric analysis of the C57BL/6J mouse brain. NeuroImage. 2007;37:683–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  22. 22.

    Almhdie A, Lopes-Pereira P, Même S, Colombier C, Brault V, Szeremeta F, et al. Chan-Vese based method to segment mouse brain MRI images: application to cerebral malformation analysis in Trisomy 21. 2009 17th Eur Signal Process Conf. 2009. p. 1883–7.

  23. 23.

    Sahin B, Aslan H, Unal B, Canan S, Bilgic S, Kaplan S, et al. Brain volumes of the lamb, rat and BIRD do not show hemispheric asymmetry: a stereological study. Image Anal Stereol. 2001;20:9–13.

    Article  Google Scholar 

  24. 24.

    Mengler L, Khmelinskii A, Diedenhofen M, Po C, Staring M, Lelieveldt BPF, et al. Brain maturation of the adolescent rat cortex and striatum: changes in volume and myelination. NeuroImage. 2014;84:35–44.

    PubMed  Article  Google Scholar 

  25. 25.

    Oguz I, Yaxley R, Budin F, Hoogstoel M, Lee J, Maltbie E, et al. Comparison of magnetic resonance imaging in live vs. post mortem rat brains. PLoS One. Public Library of Science. 2013;8:e71027.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Sörnäs R, Ostlund H, Müller R. Cerebrospinal fluid cytology after stroke. Arch Neurol. 1972;26:489–501.

    PubMed  Article  Google Scholar 

  27. 27.

    Barcikowska-Litwin M, Krajewski S, Dolińska E, Rafałowska J. Lymphocytes within the infarct area in human brain. Neuropatol Pol. 1987;25:451–60.

    CAS  PubMed  Google Scholar 

  28. 28.

    Esiri MM, Morris CS. Immunocytochemical study of macrophages and microglial cells and extracellular matrix components in human CNS disease. 2. Non-neoplastic diseases. J Neurol Sci. 1991;101:59–72.

  29. 29.

    Chuaqui R, Tapia J. Histologic assessment of the age of recent brain infarcts in man. J Neuropathol Exp Neurol. 1993;52:481–9.

    CAS  PubMed  Article  Google Scholar 

  30. 30.

    Krupinski J, Kaluza J, Kumar P, Kumar S. Immunocytochemical studies of cellular reaction in human ischemic brain stroke. MAB anti-CD68 stains macrophages, astrocytes and microglial cells in infarcted area. Folia Neuropathol. 1996;34:17–24.

    CAS  PubMed  Google Scholar 

  31. 31.

    Lindsberg PJ, Carpén O, Paetau A, Karjalainen-Lindsberg ML, Kaste M. Endothelial ICAM-1 expression associated with inflammatory cell response in human ischemic stroke. Circulation. 1996;94:939–45.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  32. 32.

    Postler E, Rimner A, Beschorner R, Schluesener HJ, Meyermann R. Allograft-inflammatory-factor-1 is upregulated in microglial cells in human cerebral infarctions. J Neuroimmunol. 2000;108:244–50.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Schwab JM, Nguyen TD, Meyermann R, Schluesener HJ. Human focal cerebral infarctions induce differential lesional interleukin-16(IL-16) expression confined to infiltrating granulocytes, CD8+ T-lymphocytes and activated microglia/macrophages. J Neuroimmunol. 2001;114:232–41.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Beschorner R, Schluesener HJ, Gözalan F, Meyermann R, Schwab JM. Infiltrating CD14+ monocytes and expression of CD14 by activated parenchymal microglia/macrophages contribute to the pool of CD14+ cells in ischemic brain lesions. J Neuroimmunol. 2002;126:107–15.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Mena H, Cadavid D, Rushing EJ. Human cerebral infarct: a proposed histopathologic classification based on 137 cases. Acta Neuropathol. 2004;108:524–30.

    PubMed  Article  Google Scholar 

  36. 36.

    Mărgăritescu O, Mogoantă L, Pirici I, Pirici D, Cernea D, Mărgăritescu C. Histopathological changes in acute ischemic stroke. Rom J Morphol Embryol. 2009;50:327–39.

    PubMed  Google Scholar 

  37. 37.

    Yilmaz A, Fuchs T, Dietel B, Altendorf R, Cicha I, Stumpf C, et al. Transient decrease in circulating dendritic cell precursors after acute stroke: potential recruitment into the brain. Clin Sci (Lond). 2009;118:147–57.

    PubMed  Article  Google Scholar 

  38. 38.

    Arsene D, Vasilescu F, Toader C, Bălan A, Popa C, Ardeleanu C. Clinico-pathological correlations in fatal ischemic stroke. An immunohistochemical study of human brain penumbra. Rom J Morphol Embryol. 2011;52:29–38.

  39. 39.

    Holfelder K, Schittenhelm J, Trautmann K, Haybaeck J, Meyermann R, Beschorner R. De novo expression of the hemoglobin scavenger receptor CD163 by activated microglia is not associated with hemorrhages in human brain lesions. Histol Histopathol. 2011;26:1007–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Enzmann G, Mysiorek C, Gorina R, Cheng Y-J, Ghavampour S, Hannocks M-J, et al. The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury. Acta Neuropathol (Berl). 2013;125:395–412.

    Article  Google Scholar 

  41. 41.

    Perez-de-Puig I, Miró-Mur F, Ferrer-Ferrer M, Gelpi E, Pedragosa J, Justicia C, et al. Neutrophil recruitment to the brain in mouse and human ischemic stroke. Acta Neuropathol (Berl). 2015;129:239–57.

    CAS  Article  Google Scholar 

  42. 42.

    Nguyen T-VV, Frye JB, Zbesko JC, Stepanovic K, Hayes M, Urzua A, et al. Multiplex immunoassay characterization and species comparison of inflammation in acute and non-acute ischemic infarcts in human and mouse brain tissue. Acta Neuropathol Commun. 2016;4:100.

  43. 43.

    Feng Y, Liao S, Wei C, Jia D, Wood K, Liu Q, et al. Infiltration and persistence of lymphocytes during late-stage cerebral ischemia in middle cerebral artery occlusion and photothrombotic stroke models. J Neuroinflammation. 2017;14:248.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  44. 44.

    Li M, Li Z, Yao Y, Jin W-N, Wood K, Liu Q, et al. Astrocyte-derived interleukin-15 exacerbates ischemic brain injury via propagation of cellular immunity. Proc Natl Acad Sci U S A. 2017;114:E396-405.

    CAS  PubMed  Article  Google Scholar 

  45. 45.

    Zrzavy T, Machado-Santos J, Christine S, Baumgartner C, Weiner HL, Butovsky O, et al. Dominant role of microglial and macrophage innate immune responses in human ischemic infarcts. Brain Pathol Zurich Switz. 2018;28:791–805.

    CAS  Article  Google Scholar 

  46. 46.

    Ren X, Akiyoshi K, Dziennis S, Vandenbark AA, Herson PS, Hurn PD, et al. Regulatory B cells limit CNS inflammation and neurologic deficits in murine experimental stroke. J Neurosci. 2011;31:8556–63.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  47. 47.

    Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006;113:2105–12.

    PubMed  Article  Google Scholar 

  48. 48.

    Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, et al. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010;115:3835–42.

    CAS  PubMed  Article  Google Scholar 

  49. 49.

    Antje S, Jan-Kolja S, Stephanie H, Nils-Martin B, Martin H, Matthias M, et al. Targeting different monocyte/macrophage subsets has no impact on outcome in experimental stroke. Stroke. 2017;48:1061–9.

    Article  CAS  Google Scholar 

  50. 50.

    Perego C, Fumagalli S, Zanier ER, Carlino E, Panini N, Erba E, et al. Macrophages are essential for maintaining a M2 protective response early after ischemic brain injury. Neurobiol Dis. 2016;96:284–93.

    CAS  PubMed  Article  Google Scholar 

  51. 51.

    Ma Y, Li Y, Jiang L, Wang L, Jiang Z, Wang Y, et al. Macrophage depletion reduced brain injury following middle cerebral artery occlusion in mice. J Neuroinflammation. 2016;13:38.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  52. 52.

    Buga A-M, Di Napoli M, Popa-Wagner A. Preclinical models of stroke in aged animals with or without comorbidities: role of neuroinflammation. Biogerontology. 2013;14:651–62.

    CAS  PubMed  Article  Google Scholar 

  53. 53.

    Herson PS, Hurn PD. Chapter 12 - Gender and the injured brain. In: Savic I, editor. Prog Brain Res [Internet]. Elsevier; 2010 [cited 2020 Jul 26]. p. 177–87. Available from: http://www.sciencedirect.com/science/article/pii/B9780444536303000129.

  54. 54.

    Backhaus P, Roll W, Beuker C, Zinnhardt B, Seifert R, Wenning C, et al. Initial experience with [18F]DPA-714 TSPO-PET to image inflammation in primary angiitis of the central nervous system. Eur J Nucl Med Mol Imaging. 2020;47:2131–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references

Funding

Open Access funding enabled and organized by Projekt DEAL. This study was supported by the Deutsche Forschungsgemeinschaft (DFG; MI 1547/3–1, MI 1547/4–1 and FOR 2879/1, DFG ME 3283/11–1, DFG ME 3283/13–1 (TB2), KL2199/5–1).

Author information

Affiliations

Authors

Contributions

All authors contributed to the study conception and design. Data collection and analysis were performed by Carolin Beuker, Jan-Kolja Strecker, and Rajish Rawal. The first draft of the manuscript was written by Carolin Beuker and Jens Minnerup, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jens Minnerup.

Ethics declarations

Conflicts of Interest/Competing Interests

HW: honoraria for Scientific Advisory Boards Biogen, Evgen, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Aventis. Speaker honoraria and travel support from Alexion, Biogen, Cognomed, F. Hoffmann-La Roche Ltd., Gemeinnützige Hertie-Stiftung, Merck Serono, Novartis, Roche Pharma AG, Genzyme, TEVA, and WebMD Global. Paid consultant for Abbvie, Actelion, Biogen, IGES, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis, and the Swiss Multiple Sclerosis Society. Research is funded by RE Children’s Foundation, Biogen, GlaxoSmithKline GmbH, Roche Pharma AG, Sanofi-Genzyme.

LK: Compensation for Scientific Advisory Boards for Alexion, Genzyme, Janssen, Merck Serono, Novartis and Roche. Speaker honoraria and travel support from Bayer, Biogen, Genzyme, Grifols, Merck Serono, Novartis, Roche, Santhera and Teva. Research support from Biogen, Novartis and Merck Serono.

CJS and WRS are inventors on the patent application “Hematopoietic factors for treatment of neurological condition” including stroke. Recently a part of the application (ALS) was granted. CJS and WRS transferred their rights to Sygnis and received a minor financial compensation upfront. In case of efficacy CJS and WRS participate in form of royalties. WRS: Compensation as PI of the AXIS I study.

SM: Speaker honoraria and travel support from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS und Teva. Research is funded by Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.

JM: Grants from EVER Pharma Jena GmbH, and Ferrer International, travel grants from Boehringer Ingelheim, and speaking fees from Bayer Vital and Chugai Pharma.

CB, RR, JKS, ASP, HM, and TR declare no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

ESM 1

(DOCX 21 kb)

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Beuker, C., Strecker, JK., Rawal, R. et al. Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis. Transl. Stroke Res. (2021). https://doi.org/10.1007/s12975-021-00887-4

Download citation

Keywords

  • Ischemic stroke
  • Immune cell infiltration
  • Inflammation
  • Meta-analysis